Bristol Children's Vaccine Centre
The Bristol Children's Vaccine Centre (BCVC) is a group of doctors, nurses and scientists working together to develop new, better ways to prevent and treat infectious diseases.
We conduct commercial and non-commercial clinical trials to evaluate novel drugs and vaccines, from small early-phase safety studies through to larger efficacy trials.
We also carry out other clinical research studies to find out more about the naturally occurring carriage of bacteria and/or viruses in healthy individuals, and how this changes in illness.
This work can take the shape of large epidemiology-type studies or smaller lab-based research projects that use human tissue samples (blood, adenoids etc.). These are obtained via donations to the Bristol Biobank.
Clinical trial to evaluate a new Hepatitis B vaccine (CONSTANT study)
University Hospitals Bristol NHS Foundation Trust is conducting a clinical research study of a vaccine against hepatitis B virus (HBV).
Hepatitis B is a serious infection of the liver caused by HBV that is spread through blood and other body fluids, and affects millions of people worldwide. Long-term (chronic) infection with HBV can lead to liver failure, cancer and even death. Once HBV infection has become chronic, treatment options are limited, therefore a better option is to prevent HBV infection by using vaccines.
This study is being done to compare an “investigational” HBV vaccine against a “standard” HBV vaccine (Engerix‑B®) that is already licensed in the United Kingdom (UK), to measure whether it is as good as the currently used vaccine. The study will also compare three lots of the study vaccine (produced at different times), to ensure that the vaccine quality is consistently good.
Approximately 3,200 healthy people aged 18-45 years who have not previously been vaccinated against HBV will be enrolled in this study at up to 40 study sites in the UK, US, Canada, and the EU. The study will last for about a year, and will involve a screening visit and five study visits, plus four telephone check-ups. Participants will receive three doses of vaccine over the course of the study, and be asked to provide blood samples on 5 occasions.
Compensation for time and inconvenience will be provided. Reasonable travel expenses associated with taking part in this study, for example to attend visits, will be reimbursed.
To find out more about the study, contact the study team on
Tel: 0117 342 9212
Tissue culture plate